

AD _____

Award Number: DAMD17-02-1-0561

TITLE: Endothelial Cell-Targeted Adenoviral Vector
for Suppressing Breast Malignancies

PRINCIPAL INVESTIGATOR: Shuang Huang, Ph.D.

CONTRACTING ORGANIZATION: The Scripps Research Institute
La Jolla, CA 92037

REPORT DATE: April 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050819042

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 2005	3. REPORT TYPE AND DATES COVERED Final (1 Apr 02 - 31 Mar 05)	
4. TITLE AND SUBTITLE Endothelial Cell-Targeted Adenoviral Vector for Suppressing Breast Malignancies			5. FUNDING NUMBERS DAMD17-02-1-0561	
6. AUTHOR(S) Shuang Huang, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Scripps Research Institute La Jolla, CA 92037 E-Mail: shuang@scripps.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Angiogenesis is essential for the growth and metastasis of solid tumors including breast cancer. In vitro and in vivo experimental models clearly demonstrate that suppressing angiogenesis leads tumor suppression. The overall goal of this proposal is to develop an adenovirus-based gene therapy approach for suppressing angiogenesis. In first year of the funding period, we have successfully constructed a human endothelial cell-targeted adenovirus gene delivery vector. In this second year of funding period, we successfully constructed endothelial cell-targeted adenoviral vector containing therapeutic genes including soluble VEGF receptor (sFlk and sFlt) and dominant negative angiogenesis-essential signaling molecules including Raf-1 and PI-3K. These vectors were found to significantly inhibit VEGF-induced human endothelial cell migration and in vitro angiogenesis. In the last year of the funding, we have focused on our effort to determine whether the endothelial cell-targeted adenoviral vector can be used to deliver anti-angiogenesis agents to block angiogenesis and tumor development in animal models. Our studies demonstrate that our approach can sufficiently inhibit both angiogenesis and breast tumor development. We believe that our endothelial cell target adenoviral vector provide a useful means for specifically delivering therapeutic agents to angiogenic tumors.				
14. SUBJECT TERMS Angiogenesis, gene therapy, adenoviral vector, endothelial cells				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7
References.....	None
Appendices.....	None

Introduction


The survival, growth and metastasis of solid tumors including breast cancer depends on the formation of new blood vessels to provide tumors with nutrients and oxygen, a process called angiogenesis. In vitro and in vivo experimental models indicate that suppressing angiogenesis can also suppress solid tumors. However, the success of this approach largely depends on whether sufficient amounts of therapeutic agents can be delivered to tumor-associated endothelial cells without causing toxic effects to other tissues/cells. Our proposal is designed to develop an endothelial cell-targeted adenoviral vector and to use the targeted vector to express high levels of anticancer therapeutic genes in the sites of angiogenic tumors specifically and efficiently.

Body

In the first year of this funding, we have developed an endothelial cell-targeted adenoviral vector (adenovirus fiber was modified by inserting NGR peptide in its HI-loop). In the second year of this funding, we constructed the endothelial cell-targeted adenoviral vector carrying anti-angiogenesis genes, soluble VEGF receptor (sFlk and sFlt) and dominant negative angiogenesis-essential signaling molecules [MEK1(-) and PI-3K(-)]. We further demonstrate that adenovirus-delivered sFlk and dominant negative PI-3K [PI-3K(-)] are capable of significantly blocking VEGF-induced cell migration and in vitro angiogenesis. In the final year of this funding, we determined the efficacy of endothelial cell-targeted adenovirus-delivered sFlk and dominant negative PI-3K to suppress breast tumor development in two established breast tumor models.

1. Athymic nude mouse model.


Exponentially growing MDA-MB-231 cells (5×10^6 cells/mouse) were subcutaneously injected at the inguinal mammary fat pad areas of 4-week old female



athymic nude mice (Harlan Spague Dawley, Inc.) and tumors were closely observed. After four weeks (a period time to allow tumor formation), mice were divided into four groups (12 animals in each group): animals receiving control virus (containing no therapeutic gene) alone, animals receiving Ad/sFlk, animals receiving Ad/PI-3K(-), and animals receiving the combination of Ad/sFlk and Ad/PI-3K(-). The amount of Ad was given at 10^9 pfu/animal. At four weeks after animals receiving Ad vectors, six animals from each group were sacrificed, then the tumors excised and weighed. Animals receiving Ad/sFlk,


Ad/PI-3K(-) and combination of both Ad vectors displayed the reduction in tumor mass of 62%, 77%, and 89% respectively comparing to animals receiving the control virus (Fig.1). These results suggest that delivering anti-angiogenic genes to the angiogenic tumors is capable of suppressing breast cancer development.

To determine the effect of endothelial cell-targeted adenovirus-delivered sFlk and PI-3K(-) on the survival of tumor-bearing nude mice, we monitored the remaining six



animals in each group daily until their death. Animals receiving control virus lived average of another 7.4 weeks. In contrast, animals receiving Ad/sFlk and Ad/PI-3K(-) lived average of 13.4 and 13.8 weeks respectively (Fig.2). In six animals receiving the combination of both Ad vectors, we have one animals are still alive after 30 weeks. The five deceased mice lived average of 20.8 weeks (Fig.2). These results suggest that suppressing angiogenesis with Ad-delivered sFlk and PI-3K(-) can significantly prolong breast cancer-bearing animal survival.

2. Human/nude mouse model.



Four-week old nude mice were anaesthetized and a 2-cm² section of skin was surgically removed on the back of animals. A pre-cut section of fresh human neonatal foreskin was sutured into the place. The grafts were bandaged securely for 4 weeks to allow appropriate healing. MDA-MB-231 cells (5X10⁶ cells/mouse) were injected intradermally and five days later, control Ad, Ad/sFlk or Ad/PI-3K(-) were administrated through the tail veins at 10⁹ pfu/animal. After six weeks, mice were sacrificed, their grafts removed and analyzed for the presence of tumors. Six mice received control Ad grew tumors at the average mass of 464mg (Fig.3). In contrast, mice received Ad.sFlk and Ad.PI-3K(-) had tumors at the average mass of 264 and 171 mg respectively

(Fig.3). In mice receiving the combination of Ad.sFlk and Ad.PI-3K(-), we did not detect tumors in two of the six mice. The mice that did grow tumors had average mass of 107 mg. These results further demonstrate the effectiveness of endothelial cell-targeted Ad-delivered anti-angiogenic genes for suppressing breast tumors.

Key Research Accomplishment

We have demonstrated that the endothelial cell-targeted Ad vector containing sFlk and dominant negative PI-3K can effectively suppress breast tumor development and prolong the survival of tumor-bearing mice.

Reportable Outcomes

Two accepted and one submitted manuscripts were partially supported by this grant:

Yu, J., Bian, D., Mahanivong, C., Chang, R.K., Zhou, W., and **Huang, S.** (2004). p38 mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. *J.Biol.Chem.*, 279:50446-50454.

Li, H., Ye, X., Mahanivong, C., Bian, D., Chun, J., and **Huang, S.** (2005). Signaling mechanisms responsible for lysophosphatidic acid- induced urokinase plasminogen activator expression in ovarian cancer cells. *J.Biol.Chem.*, 280:10564-10571.

Mahanivong, C., Bian, D., Von Seggern D.J., and **Huang, S.** (2005). An efficient strategy to alter adenovirus tropism to facilitate human endothelial cell transduction. Submitted to *J.Virol.*

Conclusions

We have generated endothelial cell-targeted Ad vectors containing sFlk and dominant negative PI-3K. In our experiments, we found that these vectors can suppress VEGF-induced human endothelial cell migration and angiogenesis using in vitro experimental models. We further demonstrated that these Ad vectors were capable of efficiently suppressing breast tumor development in experimental animal models. These studies represent an alternative therapeutic modality for breast cancer treatment.